Bio Cor Rx Inc. BICX
We take great care to ensure that the data presented and summarized in this overview for BioCorRx Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BICX
Top Purchases
Top Sells
About BICX
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Insider Transactions at BICX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
44,220
+3.44%
|
-
|
|
Jun 28
2024
|
Luisa Ingargiola |
BUY
Grant, award, or other acquisition
|
Direct |
10,204
+13.72%
|
-
|
|
Jun 28
2024
|
Lourdes Felix CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,204
+10.12%
|
-
|
|
May 31
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
22,831
+3.8%
|
-
|
|
Apr 30
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
21,552
+3.73%
|
-
|
|
Mar 28
2024
|
Luisa Ingargiola |
BUY
Grant, award, or other acquisition
|
Direct |
5,566
+9.35%
|
-
|
|
Mar 28
2024
|
Joseph J Galligan |
BUY
Grant, award, or other acquisition
|
Direct |
5,566
+2.29%
|
-
|
|
Mar 28
2024
|
Harsha Murthy |
BUY
Grant, award, or other acquisition
|
Direct |
5,566
+22.01%
|
-
|
|
Mar 28
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
24,119
+2.21%
|
-
|
|
Mar 28
2024
|
Lourdes Felix CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,566
+6.48%
|
-
|
|
Feb 29
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
16,892
+3.21%
|
-
|
|
Jan 31
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
18,269
+3.57%
|
-
|
|
Jan 16
2024
|
Louis C. Lucido President |
BUY
Open market or private purchase
|
Direct |
126
+0.03%
|
$0
$0.7 P/Share
|
|
Jan 12
2024
|
Louis C. Lucido President |
BUY
Open market or private purchase
|
Direct |
3,000
+0.63%
|
$0
$0.7 P/Share
|
|
Jan 02
2024
|
Joseph J Galligan |
BUY
Grant, award, or other acquisition
|
Direct |
6,173
+2.59%
|
-
|
|
Jan 02
2024
|
Harsha Murthy |
BUY
Grant, award, or other acquisition
|
Direct |
6,173
+30.37%
|
-
|
|
Jan 02
2024
|
Lourdes Felix CEO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,173
+7.62%
|
-
|
|
Jan 02
2024
|
Louis C. Lucido President |
BUY
Grant, award, or other acquisition
|
Direct |
6,173
+1.29%
|
-
|
|
Jan 02
2024
|
Luisa Ingargiola |
BUY
Grant, award, or other acquisition
|
Direct |
6,173
+11.31%
|
-
|
|
Sep 29
2023
|
Kent Emry |
BUY
Grant, award, or other acquisition
|
Direct |
2,858
+2.44%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 221K shares |
|---|---|
| Open market or private purchase | 3.13K shares |